Metastatic Brain Tumor
John C Breneman
The Barrett Center, Medical Science Building, University Pointe
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.
Approximately 50 participants will be in this study and will be in the treatment phase of the study for 6 months. Study procedures will be conducted such as: history, physical and neurological exam, pregnancy testing (for women of child bearing age) and a Brain MRI. You will have follow up appointments every 3 months for 1 year at which time, your participation in the study will be concluded.
Eligible Participants must be 18 years old, and have either a type of cancer that has spread to the brain (brain metastases), a meningioma or an arteriovenous malformation and will need radiosurgery as part of treatment.
For more information, please contact Alison Kastl, BS, CCRC, Director of Clinical Trials, at email@example.com or (513) 584-0436.